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Psychometric properties of two measures of psychological well-being were evaluated 
for adults with growth hormone deficiency (GHD): the General Well-being Index, 
(GWBI) – British version of the Psychological General Well-being Index, and the 12-
item Well-being Questionnaire (W-BQ12). 
Methods 
Reliability, structure and other aspects of validity were investigated in a cross-
sectional study of 157 adults with treated or untreated GHD, and sensitivity to 
change in a randomised placebo-controlled study of three months' growth hormone 
(GH) withdrawal from 12 of 21 GH-treated adults. 
Results 
Very high completion rates were evidence that both questionnaires were acceptable 
to respondents. Factor analyses did not indicate the existence of useful GWBI 
subscales, but confirmed the validity of calculating a GWBI Total score. However, 
very high internal consistency reliability (Cronbach's alpha = 0.96, N = 152), 
probably indicated some item redundancy in the 22-item GWBI. On the other hand, 
factor analyses confirmed the validity of the three W-BQ12 subscales of Negative 
Well-being, Energy, and Positive Well-being, each having excellent internal reliability 
(alphas of 0.86, 0.86 and 0.88, respectively, N from 152 to 154). There was no sign 
of item redundancy in the highly acceptable Cronbach's alpha of 0.93 (N = 148) for 
the whole W-BQ12 scale. Whilst neither questionnaire found significant differences 
between GH-treated and non-GH-treated patients, there were correlations (for GH-
treated patients) with duration of GH treatment for GWBI Total (r = -0.36, p = 
0.001, N = 85), W-BQ12 Total (r = 0.35, p = 0.001, N = 88) and for all W-BQ12 
subscales: thus the longer the duration of GH treatment (ranging from 0.5 to 10 
years), the better the well-being. Both questionnaires found that men had 
significantly better overall well-being than women. The W-BQ12 was more sensitive 
to change than the GWBI in the GH-Withdrawal study. A significant between-group 
difference in change in W-BQ12 Energy scores was found [t(18) = 3.25, p = 0.004, 
2-tailed]: patients withdrawn from GH had reduced energy at end-point. The GWBI 
found no significant change. 
Conclusion 
The W-BQ12 is recommended in preference to the GWBI to measure well-being in 
adult GHD: it is considerably shorter, has three useful subscales, and has greater 
sensitivity to change. 
Background 
 
The physical symptoms of adult growth hormone deficiency (GHD) include abnormal 
body composition with reduced lean body mass and increased central adiposity; 
reduced muscle strength and exercise performance [1]. However, adults with 
untreated GHD report symptoms of reduced psychological well-being including low 
energy, tiredness, irritability [2], anxiety, depression and mood swings [3] and it has 
been said that "psychological aspects may be at least as, if not more, important" 
than physiological [4]. To measure the effects of growth hormone (GH) treatment 
sensitive measures of patient-reported outcomes, such as quality of life (QoL), health 
status and psychological well-being, are also required in addition to measuring 
physiological outcomes. Condition-specific QoL measures in adult GHD exist [5,6], 
but QoL is not equivalent to health status or well-being, although often reported as 
such [7]. 
The questionnaire most commonly employed to measure psychological well-being in 
adult GHD has been the generic 22-item Psychological General Well-being Index 
(PGWB) [8], with six subscales (Anxiety, Depression, General Health, Positive Well-
being, Self-control and Vitality), and a Total score. Results of randomised placebo-
controlled trials providing GH treatment to adults with GHD have been mixed. In 
some studies the PGWB found no significant change [9-11], but others found, after 
six months' GH-treatment, significant improvement in Depression [12]; Vitality and 
Total well-being [13]; General Health, Positive Well-being, Vitality and Total well-
being [14]. Longer-term open-label studies of GH treatment have found 
improvements in most or all PGWB variables [15-17]. Those who continued with GH 
therapy over 9 years had significant increases in Vitality, but those who discontinued 
GH had significant decreases in General Health over the same period [18]. Some 
were British studies [9,12,14,15,18] but used the PGWB, although this American 
questionnaire does not appear to have been validated either for use in the UK or in 
adult GHD. However, a British version of the PGWB exists: the General Well-being 
Index (GWBI) [19]. This is very similar to the PGWB having only some minor 
differences in vocabulary (e.g. blue becomes sad on the British version), five 
response categories rather than the six, and in question order. 
Validation of the GWBI, in two samples of British patients with depression, indicated 
construct validity [19,20] and high internal consistency reliability for the whole scale 
(in the range 0.92 – 0.96) [19]. Ability to discriminate between subgroups in a 
primary care setting has also been demonstrated [21]. Subscales were not 
recommended owing to their high inter-correlations and lack of adequate internal 
consistency (alpha scores were not supplied) [20], although alpha scores for PGWB 
subscales have been reported (ranging from 0.72 (Self-control) to 0.88 (Anxiety) 
[8]. However, more recently Gaston and Vogl investigated the psychometric 
properties in an Australian non-clinical population and found three significant factors 
[22], rather than the six factors that might have been expected given that the GWBI 
is so similar to the six-subscale PGWB. 
The Well-being Questionnaire (W-BQ) [23] is another generic measure of 
psychological well-being. The 12-item version, the W-BQ12, is derived from the 
longer W-BQ22 [23,24], and which has been used in a number of studies to evaluate 
the effects of new treatments and interventions in diabetes [23-25], a condition for 
which it has good internal consistency and validity [25-27]. The W-BQ12, however, 
poses less respondent burden than the W-BQ22, and redresses an imbalance 
between numbers of positively worded and negatively worded items in the longer 
questionnaire [28]. The W-BQ12 has been translated into several languages, and 
psychometric evaluations of these and the original English have confirmed its 
structure and reliability for people with diabetes [25-27] and it also has good 
psychometric properties for people with macular disease [29]. 
The two studies described here presented the opportunity to evaluate the 
psychometric properties of both the GWBI and W-BQ12 in a sample of adults with 
GHD at a London hospital. The first study was a cross-sectional survey of 157 adults 
with severe GHD, GH-treated and non-GH-treated, to investigate reliability, factor 
structure, construct and concurrent validity of the questionnaires. Sensitivity to 
change was investigated in a randomised placebo-controlled study of three months' 






The GWBI has 22 questions each with five response options (scoring from 1 to 5), 
but worded differently for each question, to define the intended meaning (e.g. 
During the past two weeks, have you been waking up feeling fresh and rested? Every 
day – Most days – Less than half the time – Not often – Not at all). Half the items 
are positively worded, and half negatively worded. There are no recommended 
subscales. Scoring: The GWBI Total score is the sum of all 22 items (after reversing 
the negatively-worded items), and ranges 22 -110. Higher scores indicate worse 
well-being. 
W-BQ12 
The 12 items of the W-BQ12 are simple statements (e.g. I feel afraid for no reason 
at all), and have four response options from 0 ('not at all') to 3 ('all the time'), 
identical in all 12 items. There are three subscales of four items each: Negative Well-
being (all negatively worded items), Energy (two positively worded and two 
negatively worded items) and Positive Well-being (all positively worded). Scoring: 
Subscale scores range from 0 – 12 (higher scores indicating increased mood of the 
subscale label). The W-BQ12 General Well-being total score is the sum of all 12 
items (after reversing the Negative Well-being item scores), and ranges from 0 – 36 
(higher scores indicating better well-being). 
Other questionnaires 
Other questionnaires were also completed in these studies including the Nottingham 
Health Profile [30], the Short-form 36 (SF-36) [31], and a new hormone deficiency-
specific individualised quality of life questionnaire (HDQoL) [5], the full results for 
which have been reported previously [32-34]. 
Study 1: The cross-sectional survey 
Recruitment procedures 
Recruitment procedures have been fully described elsewhere [32], but in brief they 
were as follows. Participating patients had been diagnosed severely GH deficient as 
determined by an Insulin Tolerance or Pituitary Function Test in which insulin 
reduced blood glucose to ≤ 2.5 mmol/L with peak GH concentration ≤ 10 mU/L. 
Patients had either received GH-replacement therapy for at least six months 
immediately prior to the study or had not received GH treatment in the previous six 
months; were aged between 18–70 years; had received appropriate adrenal, thyroid 
and gonadal hormone replacement therapy as required by their hormonal condition, 
for at least 12 months prior to the study. Patients might have had adult or childhood 




Normality of distributions was investigated through standardised z (skew) values 
[35]. Some questionnaire item distributions were skewed, and finding 
transformations for these variables that did not adversely affect normal distributions 
of other items in the same questionnaire proved difficult. Item data were not 
transformed to normality, thereby sacrificing some of the accuracy of reliability and 
factor analyses for the convenience of having interpretability of original units. The 
assumption was made that if reliability were high, the factor analysis robust, and the 
number of respondents sufficiently high, then a degree of non-normality was 
acceptable. In sub-group analyses, Mann-Whitney tests were performed on skewed 
variables, and t-tests on normal data. 
Internal consistency reliability and factor structure 
Cronbach's alpha coefficient [36] was determined with an acceptable minimum alpha 
being taken as 0.7 to 0.8, depending on the number of items in a scale [37], noting 
that some consider 0.9 as the minimum for measures of differences between 
individuals [38]. Acceptable corrected item-total correlations are those >0.2 [39]. 
Factor structure was explored using Principal Components extraction with Varimax 
rotation. Salient loadings were taken as ≥ 0.4, higher than the recommended 
minimum 0.3 [40], erring on the side of caution in an effort to reduce the risk of 
spurious loadings that owed their origin to non-normality of item distributions and to 
avoid multiple loadings. 
Subgroup differences and 'familywise' error in multiple tests 
The questionnaires' sensitivity to some subgroup differences was investigated (GH-
treatment groups, and sex). The Holm's sequential Bonferroni procedure for multiple 
tests [41] was adopted in large correlation matrices and for the W-BQ12 and its 
subscales. 
Concurrent validity 
Correlations were undertaken with Mental Health, Vitality and Physical Functioning 
subscales of the widely used SF-36 health status measure also completed in this 
study [32]. SF-36 subscale scores range from 0 to100, (higher scores indicating 
better functioning). Correlations >0.7 indicated adequate convergence [42]. 
Means are reported as mean (standard deviation). 
Study 2: Prospective study of GH-withdrawal 
Preliminary sensitivity to change was assessed in a small randomised, double-blind, 
placebo-controlled study where severely GH-deficient patients were allocated to 
placebo or continued treatment with GH for a period of three months. This study has 
been fully described elsewhere [33]. The GWBI and W-BQ-12 (in a battery of several 
questionnaires) were completed at baseline and end-point. There was a general 
clinical expectation of deterioration in physiological factors during the study period 
for those withdrawn from GH treatment and that this might be accompanied by 
reduced psychological well-being. 
The Guy's and St Thomas' Hospital Trust Ethics Committee gave approval for both 
studies and patients gave written informed consent before participating. Research 




The patient sample 
Of 219 questionnaires distributed, 163 were returned (74% response rate), but six 
patients did not meet all inclusion criteria, leaving 157 data sets, (91 GH-treated and 
66 non-GH-treated patients). Most patients (96%) had multiple pituitary hormone 
deficiencies including GHD; the remainder had isolated GHD. (See Table 1 for sample 
characteristics). 
Completion rates 
The completion rates for the GWBI and W-BQ12 were very high (99.1% and 99.0% 
respectively) indicating excellent acceptability to respondents. 
Reliability and factor analyses 
GWBI 
Unforced factor analysis of the whole scale produced three factors with eigenvalues 
>1, accounting for 67.7% of the variance (Table 2). These three factors were very 
similar to those obtained for a non-clinical population where the factors were 
described as: Factor 1 ('general mood/affect'), Factor 2 ('life satisfaction/vitality') 
and Factor 3 ('poor physical health/somatic complaints') [22]. The main differences 
between the factor loadings obtained on the two studies were for item 14 tired 
exhausted, which loaded highest on Factor 2 (present study) compared to Factor 3 
(non-clinical population), and item 6 happy with personal life which loaded highest 
on Factor 1 (present study), compared to Factor 2 (non-clinical sample). There were 
double loadings >0.4 (present study) across factors for seven items, with two more 
items potentially double loading (at 0.395). 
As the original PGWB has six subscales, and only minor alterations were made when 
adapting the measure for use in Britain, a forced 6-factor analysis was conducted to 
investigate support for the original subscales. However, GWBI items did not load 
separately as intended on the six factors (Table 3). Factor 1 consisted of vitality 
items, with one general health item (Q17), and Factor 2 consisted of self-control, 
positive well-being and depression items. Factor 3 was a mix of anxiety, depression 
and positive well-being items. There was double loading of nine items on more than 
one factor and, given the lack of any clear pattern of loading, there was no support 
for a 6-subscale structure. However, the single factor produced in a forced 1-factor 
analysis of the 22 items accounted for 55.1% of the variance with all items loading 
satisfactorily ≥ 0.58, (supporting calculation of the GWBI Total score) (Table 2). 
Note that the loadings in Tables 2 and 3 reflect the fact that scores on negatively 
worded GWBI items have been reversed to allow for ease of comparison with the 
results obtained by Gaston and Vogl [22]. 
GWBI whole-scale reliability was very high, (Cronbach's alpha 0.959, standardised 
item alpha 0.96, N = 152), probably indicating some item redundancy. Corrected 
item-total correlations ranged from 0.55 to 0.83 and were very respectable, no item 
would increase scale alpha if deleted. Reliability analysis of the three potential 
subscales (items loading highest on each factor in the unforced analysis, Table 2) 
indicated that Cronbach's alpha for the 14 items on Factor 1 (general mood/affect) 
was 0.949 (N = 154), for the six items on Factor 2 (life satisfaction/vitality) was 
0.905 (N = 155) and for the two items on Factor 3 (poor physical health/somatic 
complaints) was 0.874 (N = 154). 
Investigating possible item redundancy further, some items are similar in wording 
e.g. 'fears about health' appears in Q10 (Have you been bothered by any illness, 
pains or fears about your health?) and Q19 (Have you had any worries or fears about 
your health?); 'sad' is found in Q4 (Have you felt sad, discouraged or hopeless, so 
much so that you wondered if life was worthwhile?) and Q12 (Have you felt 
disheartened and sad?). When the unforced factor analysis was conducted with 
either item Q10 or Q19 deleted from the scale, two factors emerged, with the health 
item (Q10 or Q19) loading (>0.6) on Factor 2, and the remaining items loading as 
for the original 22-item scale. 
W-BQ12 
The single factor produced in a forced 1-factor analysis, where all items loaded ≥ ± 
0.6, accounted for 56.3% of the variance, confirming the validity of the W-BQ12 
General Well-being total score. An unforced factor analysis of the whole scale 
produced two components with multiple loadings (results not shown). A forced 3-
factor analysis (74.6% of the variance) found the four Positive Well-being items and 
the two positively worded Energy items loading on Factor 1 at >0.4; all four Negative 
Well-being items loaded on Factor 2 and all four Energy items loaded on Factor 3 
with Negative Well-being item 2 (Table 4). There was some double loading found for 
items 2, 5 and 8. Forced 1-factor analyses of subscales found all items loading >0.8 
on their respective subscales, confirming the acceptability of calculating subscale 
scores. 
A high Cronbach's alpha (0.93) was obtained for the whole scale (N = 148). 
Corrected item-total correlations were satisfactory (>0.5). The alpha coefficients 
were very high for each of the 4-item subscales: Negative Well-being (0.86, N = 
153), Energy (0.86, N = 152) and Positive Well-being (0.88, N = 154), with 
corrected item-total correlations >0.65. No item would increase scale or subscale 
alpha if deleted. 
Subgroup differences 
There were no significant differences in well-being between GH-treated and non-GH-
treated patients. Mean GWBI Total of GH-treated patients was 51.2 (S.D. 15.51) and 
of non-GH-treated patients was 50.89 (17.4) (p = 0.91, t-test); mean W-BQ12 
General Well-being total of GH-treated patients was 21.84 (S.D. 8.15) and of non-
GH-treated patients was 23.18 (8.43) (p = 0.32, t-test). Nor were significant 
differences found between those with childhood onset GHD (N = 29) and adult onset 
(N = 127). Mean GWBI Total of patients with childhood-onset GHD was 52.9 (S.D. 
19.2) and those with adult-onset was 50.67 (15.61) (p = 0.52, t-test); mean W-
BQ12 General Well-being total of patients with childhood-onset GHD was 20.66 (S.D. 
8.77) and of those with adult-onset was 22.8 (8.14) (p = 0.21, t-test). Men had 
significantly better overall well-being than women (GWBI Total and W-BQ12 General 
Well-being total) and significantly reduced W-BQ Negative Well-being compared with 
women, (see Table 5). 
Correlations with duration of GH treatment 
There were significant negative correlations between duration of GH treatment and 
GWBI Total (r = -0.36, p = 0.001, N = 85) and W-BQ12 Negative Well-being (rho = 
-0.37, p < 0.001, N = 88) and significant positive correlations (N = 88) with W-BQ12 
Total (r = 0.35, p = 0.001), Positive Well-being (r = 0.33, p = 0.002), and Energy (r 
= 0.23, p = 0.029). Thus, the longer the duration of GH treatment (ranging from 0.5 
to 10 years in this patient sample), the better the well-being. 
Concurrent validity with SF-36 subscales 
GWBI Total correlated strongly and negatively with SF-36 Mental Health (-0.83) and 
Vitality (-0.82) but had lower correlations with Physical Functioning (-0.47) as might 
be expected. W-BQ12 General Well-being total correlated strongly with SF-36 Mental 
Health (0.80). W-BQ12 Energy correlated highly with Vitality (0.80); W-BQ12 
Positive Well-being and Negative Well-being correlated moderately highly with SF-36 
Mental Health (0.73 and -0.74 respectively), but their correlations with Physical 
Functioning were lower (-0.31 to 0.49) as expected. Negative correlations were 
obtained, as expected, where questionnaires are scored in the opposite direction. 
Note: all correlations were Spearman's rho and significant, p <0.001, 2-tailed, N 
ranged from 142 to 157. 
GH-Withdrawal study 
The data of 21 patients (age range 25–68 years), all but two with multiple pituitary 
hormone deficiencies, were available for analysis: 12 placebo-treated (6 men and 6 
women) and nine GH-treated (4 men and 5 women). Three months after baseline 
the serum total Insulin-like Growth Factor-I of placebo-treated patients fell from 
normal, age-related levels, mean 26.6 (13.2) nmol/L, to levels indicative of severe 
GHD, 11.6 (6.7) nmol/L, (p <0.001). Only a small, non-significant decrease was 
noted in GH-treated patients. Full details are provided elsewhere [33]. 
Completion rates of both GWBI and W-BQ12 were 100% in this study. A significant 
between-group difference in change scores in W-BQ12 Energy was found [t(18) = 
3.25, p = 0.004, 2-tailed] with scores of Placebo-group patients dropping from 6.83 
(3.64) at baseline to 5.9 (4.12) at end-point, indicating reduced energy, while GH-
treated patients' scores increased from 7.06 (2.08) to 8.13 (1.25) over this period. 
GWBI Total showed no significant change (p = 0.24). 
Discussion 
 
The two studies described here have made a useful contribution towards the 
psychometric validation of two well-being questionnaires for use in adult growth 
hormone deficiency: the General Well-being Index and the 12-item version of the 
Well-being Questionnaire. 
Despite only minor changes made to a few words and to item order when adapting 
the Psychological General Well-being Index for use in Britain [19], a forced 6-factor 
analysis of the British GWBI did not find the 22 items factoring out separately into 
PGWB subscales such as anxiety or self-control. Unforced factor analysis, however, 
produced three factors (albeit with substantial double loading), largely confirming the 
factors labelled as 'general mood/affect', 'life satisfaction/vitality', 'poor physical 
health/somatic complaints' in the earlier study by Gaston and Vogl, conducted with a 
non-clinical sample [22]. GWBI Factor 1 items (present study) covered several 
aspects of affect, and positive and negative well-being did not factor out separately 
as in the W-BQ12. Vitality (GWBI) items loaded together with positive well-being on 
Factor 2, but with the W-BQ12, the value of having a separate energy subscale was 
demonstrated in that W-BQ12 Energy was the only scale sensitive to change in the 
GH-Withdrawal study. Although the GWBI has a weak physical health factor, 
accounting for just 11% or the variance, this reflects the fact that one of the six 
subscales of the original PGWB concerned general health. However, the GWBI could 
not be described as a measure of health status as only a small proportion of items 
(3/22) concern physical health perceptions. 
The internal consistency reliability of the whole GWBI scale was very high (>0.95) 
indicating that there may well be redundancy of items, particularly as two pairs of 
items are similarly worded, adding unnecessarily to respondent burden. The two 
general health items loading on Factor 3 in the unforced factor analysis had similar 
wording, and one or the other would appear to be redundant (if either were deleted 
from the scale then only two factors emerged in the unforced analysis). Although the 
reliability of the three potential GWBI subscales was high, overlap is considerable 
and we agree with the recommendation by McKenna et al [20] that there are no 
clear subscales to the questionnaire, and only a total score should be calculated. 
Factor analysis of the W-BQ12 indicated three relatively clean factors providing 
evidence for W-BQ12 subscales of Negative Well-being and Positive Well-being and, 
although two W-BQ12 Energy items double loaded, it was possible to interpret the 
third W-BQ12 factor as an Energy subscale. There was support for the calculation of 
a total score for the questionnaire. The internal consistency reliability of subscales 
and W-BQ12 General Well-being combined scale was excellent. This high value would 
not indicate item redundancy, however, (as in the case of the GWBI), because the 
W-BQ12 is considerably shorter than the GWBI and none of the items are similar to 
each other (as in the GWBI). 
Both well-being questionnaires had very high completion rates indicating good 
acceptability to patients, an indication of face validity. The strong correlations of both 
questionnaires with appropriate scales of the SF-36 (Mental Health and Vitality) but 
lower correlations with SF-36 Physical Functioning gave support for the concurrent 
validity of both questionnaires. The moderate correlations with Physical Functioning, 
however, indicate that well-being is associated with some aspects of health status. 
There was preliminary evidence for construct validity in both GWBI and W-BQ12, 
although no prior hypotheses were formulated. Both questionnaires found significant 
differences between men and women, with women having generally lower well-being 
than men. It is a common finding that, in the general population, women have 
reduced well-being compared with men [43,44], although not all studies have found 
this [21]. Women with GHD have also tended to exhibit lower levels of well-being 
than men [10]. Both questionnaires showed correlations indicative of improving well-
being for GH-treated patients with longer periods of GH treatment, as seen in 
previous research [17]. However, neither questionnaire found significant GH 
treatment-group differences either because the questionnaires were insufficiently 
sensitive to treatment-group differences, or there were no real differences in well-
being between the two groups, possibly as a result of the fact that symptomatic 
patients were more likely to have been selected for treatment by the doctors in the 
clinics. Indeed none of the other questionnaires used in the study found GH-treated 
patients to have significantly better patient-reported outcomes (including health 
status and condition-specific quality of life) than non-treated patients [34]. It is 
possible, but perhaps more unlikely, that those receiving GH were not all adhering to 
the injection regimen (the patients' Insulin-like Growth Factor-I data at the time of 
the study were not collected). 
The small sample size in the GH-Withdrawal study resulted in low power of analysis 
but, as anticipated, W-BQ12 Energy found a significant between-treatment-group 
difference in change scores over the withdrawal period, with reduced energy in 
placebo-treated patients at end-point. This provided a very preliminary indication of 
the W-BQ12's sensitivity to change, (there was no significant finding for the GWBI). 
This is in line with results of a study in which GH was discontinued in young adults 
with GHD [45] where a significant increase in psychological complaints (on the 
Hopkins Symptom Checklist [46]) was found after 6 months' discontinuation, 
although not across 12 months' discontinuation. It is possible that the 3-month 
withdrawal period of the present study was not long enough for significant change to 
be registered by the GWBI. All the previous studies of GH-replacement therapy that 
found significant improvement in psychological well-being using the PGWB, had a 
minimum 6 months' duration [13,14,17]. Further work on sensitivity to change with 
this patient group would be valuable in a larger and longer-term longitudinal 
intervention study, where GH treatment is being offered, not withdrawn. 
The American PGWB has been the most widely used measure of psychological well-
being in adult GHD, its six subscales sensitive to change in several studies of GH 
replacement. The British GWBI, on the hand, has no subscales, and the present 
study has confirmed that none can be recommended. This could be a disadvantage in 
this hormonal condition where low energy, increased anxiety and depression are key 
psychological aspects. Therefore, on the evidence provided by the present studies, 
the W-BQ12 can be recommended in preference to the GWBI to measure 
psychological well-being in adult GHD because the W-BQ12 has: 
• excellent reliability, both of the whole scale and of the three subscales, with no 
indication of item redundancy; 
• a clear factor structure supporting the use of subscales of Negative Well-being, 
Energy and Positive Well-being; 
• fewer items (12 compared with 22 in the GWBI) and shorter response options 
(these are relatively long and vary from item to item in the GWBI, causing greater 
respondent burden); 
• preliminary evidence of sensitivity to change. 
To cover a wider range of patient-reported outcomes in adult GHD, it is 
recommended that the generic W-BQ12 be used in a battery of questionnaires that 
includes a generic measure of health status (e.g. the SF-36 [31]) and the HDQoL 
hormone deficiency-specific quality of life questionnaire [5]. 
Conclusion 
 
The W-BQ12 is recommended in preference to the GWBI to measure well-being in adult 
GHD as it is shorter, has useful subscales, has excellent internal consistency reliability 





CM was funded by a research studentship from Lilly Industries Ltd, who also provided 
partial funding for JG. CB is copyright holder of the Well-being Questionnaire, Director 
of Health Psychology Research International and receives research grants and 




CM, CB and PS conceived and designed the cross-sectional study which was 
coordinated by CM who distributed the questionnaires. JG, DR-J and PS conceived 
and designed the controlled trial of GH withdrawal which was coordinated by JG who 
carried out biochemical measurements and distributed the questionnaires to 
participants. CM carried out the psychometric and statistical analyses of 
questionnaire data and drafted the manuscript. CB contributed to the interpretation 
of psychometric analyses and manuscript preparation. All authors read and approved 
the final manuscript. 
Copyright of W-BQ questionnaire 
 
For access to and licence to use the W-BQ, contact the copyright holder, Clare 
Bradley PhD, Professor of Health Psychology, Health Psychology Research, Royal 




CM was funded by a research studentship from Lilly Industries Ltd, who also 
provided partial funding for JG. We acknowledge valuable assistance from Louise 
Breen, Research Nurse at the Endocrine Clinic of St Thomas' Hospital, and from John 
Valentine, statistician at Royal Holloway, University of London, and the essential 





Carroll PV, Christ ER, Growth Hormone Research Society Scientific Committee : Growth 
hormone deficiency in adulthood and the effects of growth hormone 
replacement: a review. 
Journal of Clinical Endocrinology and Metabolism 1998, 83(2):382-395.  
    
   
2.
  
Hunt SM, McKenna SP, Doward LC: Preliminary Report on the development of a 
disease-specific instrument for assessing quality-of-life of adults with growth 
hormone deficiency. 
Acta Endocrinol 1993, 128:37-40  
    
   
3.
  
Wallymahmed ME, Baker GA, Humphris G, Dewey M, MacFarlane IA: The development, 
reliability and validity of a disease specific quality of life model for adults with 
growth hormone deficiency. 
Clin Endocrinol 1996, 44(4):403-411.  
    
   
4.
  
Powrie J, Weissberger A, Sönksen P: Growth hormone replacement therapy for 
growth hormone-deficient adults. 
Drugs 1995, 49(5):656-663.  
    
   
5.
  
McMillan CV, Bradley C, Gibney J, Russell-Jones DL, Sönksen PH: Preliminary 
development of the new individualised HDQoL questionnaire measuring quality 
of life in adults hypopituitarism. 
Journal of Evaluation in Clinical Practice, in press.  
   
   
6.
  
McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L: The QoL-
AGHDA: An instrument for the assessment of quality of life in adults with growth
hormone deficiency. 
Qual Life Res 1999, 8(4):373-383.  
   
   
7.
  
Bradley C: Importance of differentiating health status from quality of life. 
Lancet 2001, 357(9249):7-8.  
    
   
8.
  
Dupuy HJ: The Psychological General Well-being Index (PGWB). 
In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Edited by: 
Wenger NK, Mattson ME, Furburg CD, Elinson J. New York , Le Jacq Publishing Inc; 1984. 
    
   
9.
  
Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden 
DR: Growth-hormone treatment of adults with growth-hormone deficiency - 
Results of a 13-month placebo controlled cross-over study. 
Clin Endocrinol 1992, 36(1):45-52.  
    
   
10.
  
Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA: Quality-of-
Life in adults with Growth-Hormone (GH) Deficiency - Response to treatment 
with recombinant human GH in a placebo-controlled 21-month trial. 
J Clin Endocrinol Metab 1995, 80(12):3585-3590. 
    
   
11.
  
Baum HBA, Katznelson L, Sherman JC, Biller BMK, Hayden DL, Schoenfeld DA, 
Cannistraro KE, Klibanski A: Effects of physiological growth hormone (GH) therapy 
on cognition and quality of life in patients with adult-onset GH deficiency. 
J Clin Endocrinol Metab 1998, 83(9):3184-3189 
    
   
12.
  
McGauley G, Cuneo RC, Salomon F, Sönksen P: Psychosocial well being before and 
after growth hormone treatment in adults with growth hormone deficiency. 
Hormone Research 1990, 33:(Suppl. 4):52-54.  
    
   
13.
  
Mardh G, Lundin K, Borg G, Jonsson B, Lindeberg A: Growth hormone replacement 
therapy in adult hypopituitary patients with growth hormone deficiency: 
combined data from 12 European placebo-controlled clinical trials. 
Endocrinology and Metabolism 1994, 1:(Suppl.A):43-49.  
    
   
14.
  
Carroll PV, Littlewood R, Weissberger AJ, Bogalho P, McGauley G, Sönksen PH, Russell-
Jones DL: The effects of two doses of replacement growth hormone on the 
biochemical, body composition and psychological profiles of growth hormone-
deficient adults. 
European Journal of Endocrinology 1997, 137(2):146-153 
    
   
15.
  
Mukherjee A, Tolhurst-Cleaver S, Ryder WD, Smethurst L, Shalet SM: The 
characteristics of quality of life impairment in adult growth hormone (GH)-
deficient survivors of cancer and their response to GH replacement therapy. 
J Clin Endocrinol Metab 2005, 90(3):1542-1549.  
    
   
16.
  
Svensson J, Mattsson A, Rosen T, Wiren L, Johannsson G, Bengtsson BA, Koltowska 
Haggstrom M: Three-years of growth hormone (GH) replacement therapy in GH-
deficient adults: effects on quality of life, patient-reported outcomes and 
healthcare consumption. 
Growth Horm IGF Res 2004, 14(3):207-215.  
    
   
17.
  
Wiren L, Bengtsson BA, Johannsson G: Beneficial effects of long-term GH 
replacement therapy on quality of life in adults with GH deficiency. 
Clin Endocrinol 1998, 48(5):613-620.  
    
   
18.
  
Gilchrist FJ, Murray RD, Shalet SM: The effect of long-term untreated growth 
hormone deficiency (GHD) and 9 years of GH replacement on the quality of life 
(QoL) of GH-deficient adults. 
Clin Endocrinol (Oxf) 2002, 57(3):363-370.  
    
   
19.
  
Hunt SM, McKenna SP: A British adaptation of the General Well-being Index: a 
new tool for clinical research. 
British Journal of Medical Economics 1992, 2:49-60.  
    
   
20.
  
McKenna SP, Hunt SM, Tennant A: Psychological Well-Being in Depressed-Patients. 
Int J Methods Psychiatr Res 1993, 3(4):245-251.  
    
   
21.
  
Hopton JL, Hunt SM, Shiels C, Smith C: Measuring psychological well-being. The 
adapted general well- being index in a primary care setting: A test of validity. 
Fam Pr 1995, 12(4):452-460.  
    
   
22.  Gaston JE, Vogl L: Psychometric properties of the general well-being index. 
Qual Life Res 2005, 14(1):71-75 
    
   
23.
  
Bradley C: The Well-being Questionnaire. 
In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in 
Diabetes Research and Practice. Edited by: Bradley C. Chur, Switzerland , Harwood 
Academic Publishers; 1994:89-109.  
    
   
24.
  
Bradley C, Lewis KS: Measures of psychological well-being and treatment 
satisfaction developed from the responses of people with tablet-treated 
diabetes. 
Diabetic Med 1990, 7(5):445-451 
    
   
25.
  
Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-
being with insulin glargine compared with NPH in patients with Type 1 diabetes. 
Diabetic Med 2001, 18(8):619-625 
    
   
26.
  
Pouwer F, Snoek FJ, Van Der Ploeg HM, Ader HJ, Heine RJ: The Well-being 
Questionnaire: evidence for a three-factor structure with 12 items (W-BQ12). 
Psychol Med 2000, 30(2):455-462 
    
   
27.
  
Plowright R, Witthaus E, Bradley C: Evaluating the 12-item Well-being 
Questionnaire for use in multinational trials. 
Quality of Life Research 1999, 8:650.  
    
   
28.
  
Riazi A, Ishii H, Barendse S, et al.: Well-being questionnaire (W-BQ): Translation 
and psychometric development of a short form (W-BQ12) in Japanese. 
Proceedings of the British Psychological Society 1999, 7:34.  
    
   
29.
  
Mitchell J, Bradley C: Psychometric evaluation of the 12-item Well-being 
Questionnaire for use with people with macular disease. 
Qual Life Res 2001, 10(5):465-473 
    
   
30.
  
Hunt SM, McEwen J, McKenna SP: Measuring Health-Status - a New Tool for 
Clinicians and Epidemiologists. 
Journal of the Royal College of General Practitioners 1985, 35(273):185-188.  
    
   
31.
  
Ware JE, Sherbourne CD: The MOS 36-Item Short-Form Health Survey (SF-36). 1. 
Conceptual framework and item selection. 
Med Care 1992, 30(6):473-483.  
  
   
32.
  
McMillan CV, Bradley C, Gibney J, Russell-Jones DL, Sönksen PH: Evaluation of two 
health status measures in adults with growth hormone deficiency. 
Clinical Endocrinology 2003, 58:436-445 
    
   
33.
  
McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sönksen PH: 
Psychological effects of withdrawal of growth hormone therapy from adults with 
growth hormone deficiency. 
Clinical Endocrinology 2003, 59(4):467-475 
    
   
34.
  
McMillan CV: A psychometric evaluation of measures of quality of life and related 
health outcomes in adults with growth hormone deficiency. (PhD Thesis). 
In Psychology Department. London , Royal Holloway, University of London; 2001.  
    
   
35.
  
Tabachnik BG, Fidell LS: Using Multivariate Statistics. 
1st edition. New York , Harper and Row; 1983.  
    
   
36.
  
Cronbach LJ: Coefficient alpha and the internal structure of tests. 
Psychometrika 1951, 16:297-334  
  
   
37.
  
Todd C, Bradley C: Evaluating the design and development of psychological 
scales. 
In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in 
Diabetes Research and Practice. Edited by: Bradley C. Chur, Switzerland , Harwood 
Academic Publishers; 1994.  
   
   
38.
  
Nunnally JC: Psychometric Theory. 
New York , McGraw Hill; 1978.  
    
   
39.
  
Kline P: A Handbook of Test Construction. 
London , Routledge; 1993.  
    
   
40.
  
Kline P: An Easy Guide to Factor Analysis. 
London , Routledge; 1994.  
   
   
41.
  
Holm S: A simple sequentially rejective multiple test procedure. 
Scandinavian Journal of Statistics 1979, 6:65-70.  
    
   
42.
  
Bech P: Methodological issues in individual quality of life assessment. 
In Individual Quality of Life: Approaches to conceptualisation and assessment. Edited by: 
Joyce CR, O'Boyle CA, McGee H. Amsterdam , Harwood Academic Publishers; 1999.  
    
   
43.
  
Hunt SM, McKenna SP: The Nottingham Health Profile. 
In European Guide to the Nottingham Health Profile. Edited by: Bucquet D. Montpellier, 
France , The European Group for Quality of Life and Health Measurement; 1989:1-75.  
    
   
44.  Brazier JE, Harper R, Jones NMB, Ocathain A, Thomas KJ, Usherwood T, Westlake L: 
Validating the SF-36 Health Survey Questionnaire - new outcome measure for 
primary care. 
BMJ 1992, 305(6846):160-164. 
    
   
45.
  
Stouthart PJ, Deijen JB, Roffel M, Delemarre-van de Waal HA: Quality of life of growth 
hormone (GH) deficient young adults during discontinuation and restart of GH 
therapy. 
Psychoneuroendocrinology 2003, 28(5):612-626.  
    
   
46.
  
Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L: The Hopkins Symptom 
Checklist (HSCL): a self-report symptom inventory. 
Behav Sci 1974, 19(1):1-15.  





Characteristics of the 157 patients in the cross-sectional survey 
 
 GH treatment 
(Maximum N = 
91) 
No GH treatment 
(Maximum N = 
66) 
 
Women 51 33 
Men 40 33 
Childhood onset of GHD 21 9 
Adult onset of GHD 70 57 
Isolated GHD 5 1 
Multiple pituitary hormone deficiencies 86 65 
Mean age (SD) in years 47.1 (12.59) 51.32 (12.41) 
[range] [23.75–70.92] [23.83–70.92] 
Mean duration GHD (SD) in years (adult onset 
patients) 
13.02 (6.78) 13.18 (7.84) 
Mean duration GH Treatment (SD) in years 3.6 (2.39) - 
[range] [0.5–10.17] - 
BMI (kg/m2) (SD) 27.16 (5.54) 27.99 (5.25) 
Height (cms) (SD) 167.5 (10.53) 168.7 (10.6)  
 
GWBI loadings on unforced and forced 1-factor analyses‡ 
 
Question Factors in an unforced analysis Forced 1-factor 
 
 1 2 3  
 
Q1 feel in general .586 .532 .222 .821 
Q2 bothered by nerves* .669 .136 .104 .588 
Q3 in firm control .678 .459 .026 .772 
Q4 sad hopeless* .644 .373 .114 .724 
Q5 under stress* .638 .066 .395 .620 
Q6 happy with personal life .550 .486 .146 .740 
Q7 losing control* .711 .082 .126 .591 
Q8 anxious upset* .782 .220 .347 .801 
Q9 wake up rested .284 .699 .231 .718 
Q10 illness pain* .159 .304 .861 .592 
Q11 life full of interest .316 .675 .090 .678 
Q12 disheartened sad* .728 .382 .308 .853 
Q13 stable sure .618 .545 .057 .795 
Q14 tired exhausted* .351 .667 .374 .792 
Q15 depressed* .744 .395 .250 .853 
Q16 tense* .686 .365 .117 .749 
Q17 well enough to do things .286 .632 .408 .737 
Q18 energy vitality .147 .822 .275 .715 
Q19 worries about health* .289 .376 .762 .695 
Q20 active vigorous .194 .841 .265 .757 
Q21 cheerful .616 .590 .063 .825 
Q22 relaxed .645 .521 .109 .816 
 
% of variance 30.8 25.9 11.0 55.1  
 
‡Principal Components extraction. 
*Negatively worded item scores have been reversed for comparison with factor analyses conducted 
by Gaston and Vogl [22]. 
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are 








 1 2 3 4 5 6 
 
Q1 feel in general .424 .437 .282 .386 .216 .203 
Q2 bothered by nerves* .113 .233 .207 .153 .117 .878 
Q3 in firm control .343 .447 .279 .385 .027 .384 
Q4 sad hopeless* .220 .698 .100 .390 .179 .146 
Q5 under stress* .063 .216 .749 .135 .294 .099 
Q6 happy with personal life .298 .225 .531 .524 .129 -.015 
Q7 losing control* .132 .807 .284 -.009 .068 .107 
Q8 anxious upset* .204 .523 .530 .181 .286 .274 
Q9 wake up rested .686 .156 .201 .258 .157 .156 
Q10 illness pain* .314 .090 .183 .107 .855 .024 
Q11 life full of interest .357 .056 .095 .746 .210 .166 
Q12 disheartened sad* .267 .426 .500 .386 .289 .225 
Q13 stable sure .340 .488 .200 .539 .112 .197 
Q14 tired exhausted* .705 .175 .357 .183 .254 .124 
Q15 depressed* .321 .490 .412 .314 .223 .339 
Q16 tense* .421 .288 .649 .114 -.043 .313 
Q17 well enough to do things .690 .211 .150 .120 .325 .239 
Q18 energy vitality .828 .184 .106 .239 .189 -.036 
Q19 worries about health* .350 .196 .168 .191 .775 .147 
Q20 active vigorous .799 .157 .091 .328 .213 .078 
Q21 cheerful .369 .412 .357 .592 .087 .069 
Q22 relaxed .377 .193 .497 .474 .080 .347 
 
% variance 19.9 14.2 13.4 12.8 9.5 7.5  
 
‡Principal Components extraction. 
*Negatively worded item scores have been reversed for comparison with factor analyses conducted 
by Gaston and Vogl [22]. 
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are 




W-BQ12 loadings on forced 3-factor and 1-factor analyses ‡ 
 





 1 2 3  
 
1: crying spells*(Negative Well-
being) 
-.357 .753 .185 -.732 
2: downhearted* (Negative Well-
being) 
-.313 .575 .511 -.773 
3: afraid no reason* (Negative Well-
being) 
-.125 .866 .127 -.603 
4: upset panicky* (Negative Well-
being) 
-.248 .805 .213 -.698 
5: energetic active (Energy) .691 -.130 -.436 .763 
6: dull sluggish* (Energy) -.321 .260 .825 -.772 
7: worn out* (Energy) -.291 .210 .862 -.744 
8: wake rested (Energy) .646 -.135 -.449 .742 
9: happy (Positive Well-being) .711 -.325 -.327 .823 
10: lived life wanted (Positive Well-
being) 
.769 -.287 -.176 .768 
11: eager tackle tasks (Positive 
Well-being) 
.829 -.172 -.285 .803 
12: cope (Positive Well-being) .772 -.350 -.093 .761 
 
% variance 31.37 23.18 19.99 56.3  
 
‡Principal Components extraction. 
*Negatively worded items, the raw scores of which have not been reversed. 
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are 




Means for men and women in the cross-sectional survey 
 
 Men Women Significance of differences
 Mean (SD) 
[Median] 
(Minimum N = 71)
Mean (SD) 
[Median] 
(Minimum N = 81)
 
 





24.50 (7.86) [25] 20.55 (8.23) [21] t(154) = 3.05, p = 0.003 
Negative Well-being 1.84 (2.32) [1] 3.68 (2.89) [3] U = 1853.5, p < 0.001, N = 
157 
Energy 6.87 (3.32) [7] 5.92 (3.20) [6] n.s (p = 0.07) 
Positive Well-being 7.47 (3.16) [8] 6.36 (3.33) [7] n.s (p = 0.035)*  
 
GWBI: score range 22 – 110 (lower score indicates better well-being). 
W-BQ12: subscale score range 0 – 12 (higher scores indicating increased mood of the subscale 
label); General Well-being total range 0 – 36 (higher score indicating better well-being). 
*Not significant after Bonferroni correction (required p value of 0.05/3 = 0.017) applied. 
 
